News and Announcements
Specialised Therapeutics Australia Supporting OncoSil Study
- Published April 20, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, will collaborate with independent biopharmaceutical company Specialised Therapeutics Australia (STA) to support the company’s global clinical study program examining OncoSil Medical’s proprietary technology in combination with different chemotherapy regimens.
KEY TAKEAWAYS:
- Independent pharmaceutical company Specialised Therapeutics Australia (STA) to support Oncosil Medical global Pancreatic Cancer study.
- STA to supply subsidised ABRAXANE®(nanoparticle albumin-bound paclitaxel) to Australian sites for clinical study.
- ABRAXANE® is marketed in Australia by STA under license from Celgene Corporation.
- Majority of patients recruited at five key Australian trial sites expected to be provided gemcitabine plus ABRAXANE® chemotherapy combination.
Under the terms of the arrangement, STA has authorised a significantly-subsidised supply of ABRAXANE to be used by all Australian sites participating in the global study. STA markets ABRAXANE® in Australia & New Zealand exclusively under license from the Celgene Corporation.
Australian study participants will all receive OncoSil™ plus FOLFIRINOX, or Oncosil plus a gemcitabine/ABRAXANE combination chemotherapy treatment. It is expected that most Australian patients enrolled will receive the gemcitabine/ABRAXANE chemotherapy combination.
STA Chief Executive Officer Mr Carlo Montagner said he was pleased to collaborate with Oncosil on the global study and looked forward to potentially changing treatment paradigms for pancreatic cancer.
Commenting on support of the trial, OncoSil Chief Executive Officer, Daniel Kenny said:
“We are extremely pleased to receive the generous support of Specialised Therapeutics Australia for the Australian arm of our global pancreatic study, and are greatly encouraged by the interest our study continues to generate globally.”
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
